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6-OHDA - 6-hydroxydopamine hydrobromide   
ACE2 - angiotensin converting enzyme 2 
AT-1 receptors - angiotensin II type I receptor   
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CFS - chronic fatigue syndrome 
DA - dopamine 
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Sindrom posturalne ortostatske tahikardije 
Luka Crnošija, Ivan Adamec, Antonija Mišmaš, Mario Habek  
Sažetak 
 
Ortostatska intolerancija se može opisati kao nemogućnost toleriranja uspravnog 
stava uz olakšanje simptoma nakon zauzimanja ležećeg položaja. Sindrom 
posturalne ortostatske tahikardije (POTS) je oblik ortostatske intoleracije definiran 
kao kontinuiran porast srčane frekvencije za ≥30 otkucaja u minuti ili kao porast 
frekvencije na vrijednost od ≥120 otkucaja u minuti unutar 10 minuta od početka 
stajanja ili head-up tilt testa uz pojavu simptoma ortostatske intolerancije i odsutnost 
ortostatske hipotenzije. Pacijenti kojima je dijagnosticiran POTS su uglavnom žene, s 
omjerom žena prema muškarcima 4-5:1, te starosti između 15 i 50 godina. Nekoliko 
patofizioloških mehanizama je moguće uključeno u razvoj POTS-a. Neki od njih su: 
distalna periferna neuropatija, poremećaji centralne kontrole simpatičkog živčanog 
sustava, oštećenje sinaptičkih mehanizama ponovnog unosa norepinefrina, 
poremećaji renin-angiotenzin-aldosteron osovine, promjene u sintetičkom putu 
norepinefrina. Najčešći simptomi povezani s POTS-om su omamljenost, presinkopa, 
slabost i palpitacije. Pogoršanje simptoma sa stajanjem i olakšanje nakon 
zauzimanja ležećeg položaja je karakteristično obilježje POTS-a. Pri postavljanju 
dijagnoze koriste se aktivni test stajanja i pasivni head-up tilt test, zajedno s 
detaljnom povijesti bolesti i kliničkim pregledom. Nefarmakoterapijski pristup liječenju 
POTS-a podrazumijeva povećan unos soli i vode te vježbanje. Farmakoterapija je 
usmjerena prema povećanju volumena tekućine, povećanju periferne vakularne 
rezistencije i smanjenju centralne aktivnosti simpatičkog živčanog sustava. Velik broj 
pacijenata iskusi znatno poboljšanje nakon točno postavljene dijagnoze i pravilnog 
liječenja. 
 
Ključne riječi: ortostatska intolerancija, sindrom posturalne ortostatske tahikardije, 
patofiziologija, neuropatski POTS, hiperadrenergički POTS, dijagnostika, terapija    
 
 
 
The postural orthostatic tachycardia syndrome  
Luka Crnošija, Ivan Adamec, Antonija Mišmaš, Mario Habek  
Summary 
 
Orthostatic intolerance(OI) can be defined as inability to tolerate upright posture 
relieved with recumbence. Postural orthostatic tachycardia syndrome(POTS) is a 
form of orthostatic intolerance defined as sustained increase in heart rate(HR) of ≥30 
bpm or increase of HR to ≥120 bpm within 10 min of standing or head-up tilt 
associated with symptoms of orthostatic intolerance and absence of orthostatic 
hypotension. POTS patients are mostly female, with female to male ratio of 4-5:1, 
and age range from 15 to 50. Several pathophysiological mechanisms are thought to 
underly POTS. Some of possible mechanisms are distal peripheral neuropathy, 
abnormalities of central control of sympathetic nervous system, impaired synaptic 
norepinephrine (NE) reuptake, renin-angiotensin-aldosterone axis disturbance and 
altered NE synthetic pathway. The most common symptoms related to POTS are 
light-headedness, presyncope, weakness and palpitations. Exacerbation of 
symptoms with standing and symptoms relieved with recumbence is characteristical 
POTS feature. Active stand test and passive head-up tilt table (HUT) test are used in 
diagnosing POTS, along with detailed history and examination. Non-pharmacological 
therapy of POTS includes increase in daily salt and water intake, and exercise 
training. Pharmacological therapy is directed at expanding fluid volume, increasing 
peripheral vascular resistance and reducing central sympathetic activity. Majority of 
patients experience substantial improvement, after correct diagnosis and suitable 
therapy. 
 
Keywords: orthostatic intolerance,postural orthostatic tachycardia syndrome, 
pathophysiology, neuropathic POTS, hyperadrenergic POTS, diagnostics, therapy 
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INTRODUCTION  
 
Orthostatic intolerance(OI) can be 
defined as inability to tolerate upright 
posture relieved with recumbence. 
Patients with OI experience 
characteristic symptoms and signs 
during orthostasis. These include loss 
of consiousness, visual difficulties, 
lightheadedness-dizziness, headache, 
fatigue, orthostatic hypotension and 
sometimes hypertension, 
weakness,nausea and abdominal pain, 
sweating, tremulousness. (Stewart 
2012) Depending on the level of 
sympathetic activity patients with OI 
can be classified in two types. One 
type comprises patients with 
diminished symapthetic activity who 
develop hypotension during standing. 
This is acute in those with vasovagal 
syncope and chronic in patients with 
central or peripheral 
neurodegenerative diseases. In 
second type patients have increased 
sympathetic activity, without 
development of hypotension and with 
notable tachycardia as a response to 
orthostasis. Latter is referred to as 
postural tachycardia syndrome. 
(Kaufmann 2003) 
The postural tachycardia syndrome 
(POTS) is a form of orthostatic 
intolerance defined as a sustained 
heart rate (HR) increment of ≥30 bpm 
(Freeman et al. 2011; Carew et al. 
2009; Abed et al. 2012) or increase of 
heart rate to ≥120 bpm within 10 min of 
standing or head-up tilt associated with 
symptoms of orthostatic intolerance 
and absence of orthostatic 
hypotension. For individuals aged 12 – 
19 years the required increment is at 
least 40 bpm. (Freeman et al. 2011) 
Diehl proposes a surrogate criterion for 
diagnosing POTS in patients with 
typical symptoms but not fulfilling the 
HR increment of ≥30 bpm or HR  ≥120 
criterion as HR increase between 
minutes 5 and 10 of more than 8 bpm 
during head-up tilt test. (Diehl 2005) 
The aim of this review is to investigate 
and summarize latest literature on 
postural orthostatic tachycardia 
syndrome. 
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EPIDEMIOLOGY 
 
POTS patients are mostly female, with 
female to male ratio of 4-5:1, and age 
range from 15 to 50 (Carew et al. 
2009), but with relatively few patients 
over the age of 40 years. (Thieben et 
al. 2007) These demographics may be 
due to the effect of female sex 
hormones on adrenergic receptors 
sensitivity and norepinephrine (NE) 
metabolism. (Hart et al. 2011; Edgell et 
al. 2012) The true prevalence is not 
known, but is likely to be higher than 
170 cases per 100,000. (Mathias et al. 
2012) 
 
PATHOPHYSIOLOGY  
 
Normal physiology of standing 
 
Within a few seconds of assuming 
upright from previously supine position 
300 – 800 mL of blood is gravitated 
downwards from the thorax into the 
abdomen and lower limbs thus 
decreasing venous return to the right 
side of the heart causing reduction in 
stroke volume and cardiac output. 
These changes are then registered by 
arterial baroreceptors and 
cardiopulmonary mechanoreceptors 
leading to activation of compensatory 
reflexes – increased sympathetic and 
reduced parasympathetic nervous 
system output with final outcomes of  
peripheral arterial vasoconstriction and 
reduced vagal tone to the heart with 
cardio-acceleration. (Carew et al. 
2009) Normal subjects react with 5 to 
15 bpm increase in heart rate, systolic 
blood pressure remains stable and 
diastolic blood pressure rises slightly 
(about 5 – 10 mmHg). (Carew et al. 
2009; Diehl 2005) It is important to 
notice that this reaction is swift and 
occurs within the first minute of 
assuming the upright position in normal 
subjects. (Diehl 2005) 
 
Several underlying mechanisms are 
thought to be involved in the 
pathophysiology of POTS: 
Neuropathic  
 
Some studies link POTS with partial 
dysautonomia, which predominantly 
affects lower limbs. Evidence 
supporting this hypothesis will be 
mentioned hereafter. Jacob et al. 
(Jacob et al. 2000) examined 
sympathetic nervous system function 
by measuring norepinephrine-spillover 
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in response to three stimuli – cold 
pressor test, nitropruside and tyramine 
infusion.  These stimuli increased 
norepinephrine-spillover to similar 
extent in arms of normal subjects and 
POTS patients, but failed to increase it 
in the legs of patients. One study 
(Stewart 2002) shows that arterial 
vasoconstriction, which is normal 
response to orthostasis, is impaired in 
POTS patients. This finding is 
consistent with defective 
norepinephrine secretion. (Jacob et al. 
2000; Stewart 2002) Carson et al. 
(Carson et al. 2001) made animal 
model of neuropathic tachycardia 
syndrome. Partial dysautonomia in rats 
was achieved by selectively lesioning 
peripheral postganglionic sympathetic 
neurons using neurotoxin 6-
hydroxydopamine hydrobromide (6-
OHDA) resulting in significant heart 
rate increase. Vascular α1-sensitivity 
examined with selective agonist 
phenylephrine was also increased after 
administration of 6-OHDA. Latter 
finding is consistent with early work of 
Streeten (Streeten 1990) in which he 
describes hypersensitivity of feet veins 
to NE infusion typical of denervation. 
Distal sudomotor abnormalities can be 
found in approximately half of patients 
with POTS (Thieben et al. 2007; Peltier 
et al. 2010), although this finding does 
not appear to correlate with symptom 
measurements. (Peltier et al. 2010) 
Taking these findings into account it 
can be concluded that neuropathic 
form of POTS is caused by distal 
peripheral neuropathy resulting in 
inadequate vascular response to 
orthostatic stress. This leads to 
excessive venous blood pooling and 
increased capillary filtration in lower 
extremities (Diehl 2005) causing 
functional decline in circulatory volume, 
which results in a compensatory 
increase in HR and myocardial 
contractility. Neuropathic POTS is the 
most common form of POTS. (Kanjwal 
et al. 2011; Grubb 2008) 
 
Hyperadrenergic 
 
Hyperadrenergic form of POTS is less 
frequent, encompassing about 10% of 
POTS patients. Patients with this form 
of POTS often display orthostatic 
hypertension, significantly elevated 
serum norepinephrine (>600 pg/mL) on 
standing or exaggerated response to 
intravenous isoproterenol. This group 
of patients appear to have 
abnormalities of central control of 
sympathetic nervous system or 
defective norepinephrine uptake 
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resulting in excess systemic NE 
spillover. (Carew et al. 2009; Kanjwal 
et al. 2011; Grubb 2008; Thanavaro & 
Thanavaro 2011) Some studies 
(Garland 2007; Lambert et al. 2008; 
Shannon et al. 2000) reported 
abnormally low concentration of 
plasma dihydroxyphenilglycol (DHPG), 
intraneural NE metabolite, in relation to 
NE concentration, providing evidence 
of impaired NE uptake. In some 
patients hyperadrenergic response 
may be compensatory reaction to 
hypovolemia or peripheral neuropathy 
with venous pooling. (Carew et al. 
2009)  
 
Genetic  
 
Norepinephrine transporter (NET) is 
presynaptic transporter responsible for 
the clearence of approximately 70% of 
synaptic NE. (Garland 2007) Heart is 
more sensitive to impairments in NE 
reuptake because cardiac sympathetic 
nerves recapture at least 80% of 
released NE. (Richard et al. 2012) 
Point mutation of gene encoding NET 
resulting in 98% loss of function has 
been recorded in one POTS patient. 
(Shannon et al. 2000) Two studies 
(Lambert et al. 2008; Richard et al. 
2012) recorded reduced NET protein 
expression in POTS patients. In work 
by Schroeder et al. (Schroeder et al. 
2002) POTS-like phenotype was 
achieved in healthy subjects by 
administering 8mg of reboxetine, 
selective NET blocker. Impaired NE 
clearance in the synaptic cleft may 
result in excess NE spillover and 
consequent elevated NE plasma 
levels. The relation between 
impairment of NE reuptake and POTS 
symptoms is unknown (Lambert et al. 
2008; Richard et al. 2012), except for 
tachycardia, which might be explained 
by failure of clearance of NE from 
cardiac sympathetic nerve synaptic 
spaces. (Richard et al. 2012)  
 
Renin-angiotensin-aldosterone 
system and blood volume 
perturbation 
 
The renin-angiotensin-aldosterone 
system (RAAS) plays vital role in blood 
volume control. In response to 
hypovolemia juxtaglomerular cells 
secrete renin, which then enzymatically 
acts on its substrate, angiotensinogen, 
and produces angiotensin I (Ang I). 
Ang I is then converted to angiotensin 
II (Ang II) via systemic or locally 
produced ACE (angiotensin converting 
enzyme). Ang II promotes sodium and 
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water retention, both directly by 
stimulating sodium reabsorption in the 
proximal tubule and indirectly by 
stimulating aldosterone secretion. 
Mineralocorticoid aldosterone 
regulates sodium transport at several 
sites in the kidney thus controlling 
water retention with effect on plasma 
volume. (Raj et al. 2005; Mustafa et al. 
2011; Stewart et al. 2006) Ang II is 
further degradated to Ang-(1-7) by 
ACE2 (angiotensin converting enzyme 
2). ACE2 also converts Ang I to Ang-
(1-9), which is thereafter converted to 
Ang-(1-7). Binding of Ang-(1-7) to Ang-
(1-7) receptors induces vasodilatation. 
(Stewart et al. 2009) Ang II has various 
other effects besides already 
mentioned. Ang II is involved in a 
control loop as negative feedback to 
renin production. (Stewart et al. 2006) 
Ang II can increase central 
sympathetic outflow by binding to AT-1 
receptors (Angiotensin II Type I 
receptor) in the circumventricular 
organs of the brain. (Mustafa et al. 
2011) It can also increase the release 
of NE from ganglionic and 
postganglionic sympathetic nerves 
(Mustafa et al. 2011; Stewart et al. 
2006) and inhibit NE reuptake in the 
nerve terminals with consequential 
effect on vasoconstriction. (Stewart et 
al. 2006) It also has direct 
vasoconstrictive action by binding to 
AT-1 receptors on smooth muscle 
cells. Ang II has been shown to 
decrease bioavailable NO (nitric 
oxide). (Stewart et al. 2006) 
Essentially, Ang II is a potent 
vasoconstrictor and important regulator 
of plasma volume. 
Some POTS patients exhibit low blood 
volume and inappropriately low plasma 
renin activity (PRA) and aldosterone 
concentration (Richard et al. 2012; Raj 
et al. 2005; Mustafa et al. 2011; 
Stewart et al. 2006), a state sometimes 
referred to as 'renin-aldosterone 
paradox'. (Raj et al. 2005) In work by 
Raj et al. (Raj et al. 2005) patients with 
POTS had a mean plasma volume 
deficit of almost 350 mL. At least two 
studies (Stewart et al. 2006; Jacob et 
al. 1997) reported positive correlation 
between PRA and blood volume in 
POTS patients with low blood volume, 
when negative correlation would be 
expected. Several studies (Mustafa et 
al. 2011; Stewart et al. 2006; Mustafa 
et al. 2012) reported POTS patients 
with increased level of plasma Ang II. 
Mustafa et al. (Mustafa et al. 2012) 
reported blunted systemic  
vasopressor, but not renal vascular or 
adrenal secretionary response to Ang 
II infusion in patients with POTS. This 
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study also reports POTS patients to 
have blunted baseline spontaneous 
baroreflex sensitivity (BRS) which 
showed significant negative correlation 
to baseline levels of plasma Ang II. 
Mustafa et al. (Mustafa et al. 2012) 
hypothesise that high levels of Ang II 
could be explained by decreased 
ACE2 activity. This hypothesis is 
reinforced with findings of another 
study (Crackower et al. 2002) in which 
targeted disruption of ACE2 in mice 
resulted in increased Ang II levels. 
Work by Stewart et al. provides 
evidence for latter hypothesis, but they 
also hypothesise that defective ACE2 
resulting in decreased levels of Ang-(1-
7) might contribute to excessive 
vasoconstriction found in some POTS 
patients. (Stewart et al. 2006; Stewart 
et al. 2009)This subgroup of POTS 
patients are referred to as low-flow 
POTS patients. (Stewart et al. 2009)  
This data suggest that defects in RAAS 
may play important role in 
pathophysiology of POTS, particularly 
in a subset of POTS patients with low 
blood volume and increased level of 
Ang II. 
 
Altered norepinephrine synthetic 
pathway 
 
NE is synthesised via tyrosine 
hydroxylation to DOPA 
(dihydroxyphenylalanine), DOPA 
decarboxylation to DA (dopamine). DA 
is then converted to NE through 
dopamine beta hydroxylase (DBH) 
action. Garland et al. (Garland 2007) 
measured DOPA and DA in POTS 
patients for the first time and found 
significantly increased level of DA, 
along with reduction in supine DOPA. 
Authors hypothesised that higher 
NE/DOPA ratio in combination with a 
higher plasma DA may be consistent 
with acivation of either DOPA 
decarboxylase or DBH in POTS 
patients. This could explain high 
plasma NE in some POTS patients. 
 
„The Grinch syndrome“ 
 
In study by Fu et al. (Fu et al. 2010) 27 
POTS patients were submitted to 
autonomic function test, cardiac MRI 
and 19 patients completed 3-month 
exercise training program. Following 
results were obtained: blood and 
plasma volume were markedly reduced 
in patients, left ventricular mass in 
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POTS patients was much smaller 
compared to healthy sedentary 
controls, patients had smaller cardiac 
output and stroke volume in both 
supine and upright postures, as well as 
greater peripheral resistance than 
controls. In 19 patients who completed 
3-month training program peak oxygen 
uptake, blood volume and plasma 
volume increased significantly. Ten out 
of 19 patients no longer met POTS 
criteria after training. The orthostatic 
tachycardia observed in these patients 
appeared to be a physiological 
compensatory response to the smaller 
stroke volume, which was attributable 
to cardiac atrophy and reduced blood 
volume. These results suggest that 
POTS may be a consequence of 
„deconditioning” (i.e. cardiac atrophy 
and hypovolemia), and that carefully 
prescribed exercise training can be 
used as a non-drug treatment for 
patients with POTS. Authors proposed 
new term for POTS to be „The Grinch 
syndrome“ after the main character in 
Dr. Seuss's book  „How the Grinch 
Stole Christmas” who had a heart that 
was „two sizes too small“ emphasizing 
that a small heart is the primary 
abnormality and target for therapy. 
 It is likely that pathophysiological 
mechanisms mentioned here are 
intertwined and that POTS is a result of 
their combination. 
  
CLINICAL MANIFESTATIONS 
 
About half of patients with neuropathic 
form of POTS experience acute or 
subacute onset of symptoms, often 
preceded by viral illness. It is presently 
felt that neuropathic POTS is of 
autoimmune nature in many cases, 
which is supported by the presence of 
acetylcholine receptor ganglionic (G-
AchR) antibody (Thieben et al. 2007; 
Kanjwal et al. 2011; Sandroni & Low 
2009) in 15-25% of POTS patients. 
(Terlizzi et al. 2008) Some patients 
report that their symptoms begin after 
pregnancy, surgery, sepsis or trauma. 
(Mathias et al. 2012; Peltier et al. 2010; 
Kanjwal et al. 2011) On the other hand, 
patients with hyperadrenergic form of 
POTS often describe a more gradual 
and progressive appearance of 
symptoms over time rather than abrupt 
onset. (Grubb 2008; Shannon et al. 
2000) One case report (Terlizzi et al. 
2008) attributes the onset of reversible 
POTS to inadvertent overuse of Red 
Bull®. POTS may be secondary to a 
variety of conditions that produce a 
state of peripheral autonomic 
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deinnervation or vascular 
unresponsiveness with relative sparing 
of cardiac innervation. A frequent 
cause of secondary POTS is chronic 
diabetes mellitus. Other possible 
causes are  amyloidosis, sarcoidosis, 
alcoholism, lupus, Sjögren syndrome, 
chemotherapy and heavy metal 
poisoning. POTS can be a form of 
paraneoplastic syndrome that can be 
seen with adenocarcinomas of the 
lung, breast, ovary and pancreas. 
(Grubb 2008) 
Symptoms associated with POTS are 
numerous. Thieben et al. (Thieben et 
al. 2007) made retrospective study 
involving 152 POTS patients. Clinical 
features documented in this study will 
be listed hereafter. Symptoms 
presumably related to cerebral 
hypoperfusion: light-headedness, 
77.6%;  presyncope,  60.5%;  and  
weakness,50.0%. Symptoms  
presumed  to  be  associated  with  
autonomic  overactivity: 
palpitations,75.0%; tremulousness, 
37.5%; shortness of breath, 27.6%; 
and chest wall pain, 24.3%. Sudomotor 
symptoms: loss  of  sweating,  5.3%;  
and  hyperhidrosis,  9.2%. Several of 
the chronic symptoms reported may 
reflect dysautonomia:  gastrointestinal  
complaints,  including  bloating, 23.7%;  
nausea,  38.8%;  vomiting,  8.6%;  
abdominal  pain, 15.1%; constipation, 
15.1%; diarrhea, 17.8%; bladder 
dysfunction,  9.2%;  and  pupillary  
dysfunction,  3.3%. Generalized 
complaints: 48.0% experienced  
fatigue,  31.6% experienced  
pronounced  sleep disturbance, 27.6% 
had migraine headache, and 15.8% 
had myofascial pain. Kanjawal et al. 
(Kanjwal et al. 2011) retrospectively 
analyzed 27 patients with 
hyperadrenergic POTS and came over 
next results: 55-65% of patients 
reported symptoms of hyperadrenergic 
state in form of anxiety, tremulousness 
and excessive sweating; orthostatic 
palpitation was reported by 13(48,2%) 
and syncope by 11(40,7%) patients. 
About 30% of POTS patients have 
neurally mediated syncope. (Raj 2006) 
Symptoms get worse with standing and 
are relieved with recumbence. (Raj 
2006) Aggravating factors include heat 
or exercise (53,3%), post-prandial 
symptoms (23,7%), and worsening at 
time of menses (14,5%). (Thieben et 
al. 2007) Intensity of symptoms is 
variable. Some patients are severely 
affected and are unable to work, attend 
school or participate in recreational 
activities resulting in substantial 
morbidity. (Fu et al. 2010) 
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The principal clinical sign of POTS is 
abnormal tachycardia on assumption 
of upright posture. The second 
frequent sign is acrocyanosis, which 
can extend from the feet to above the 
level of knees, with occurrence of 40-
50% during standing. (Raj 2006) Other 
signs are rare and include pupillary 
dysfunction and symptoms consisted 
with peripheral neuropathy. (Carew et 
al. 2009) 
 
ASSOCIATED  AND 
OVERLAPPING CONDITIONS 
 
Chronic fatigue syndrome (CFS)/ 
Myalgic encephalomyelitis (ME) 
 
Overlapping between clinical 
manifestations of POTS and chronic 
fatigue syndrome (CFS), also known 
as myalgic encephalomyelitis, has 
been documented in literature. 
(Thieben et al. 2007; Jacob et al. 2000; 
Hoad et al. 2008; Okamoto et al. 2012) 
The prevalence of POTS in CFS 
patients has ranged from 19% to 70%, 
while studies in cohorts of patients 
selected for POTS have shown a 
prevalence of chronic fatigue between 
48 and 77%, and CFS between 17 and 
23%. (Jacob et al. 2000; Hoad et al. 
2008; Okamoto et al. 2012) In work by 
Okamoto et al. (Okamoto et al. 2012) 
out of 47 POTS patients enrolled in the 
study 30(64%) fulfilled criteria for CFS. 
This study also compared groups of 
POTS patients with and without CFS 
and found that most common 
symptoms were unrefreshing sleep, 
impaired memory or concentration and 
muscle pain.  
 
Multiple sclerosis 
 
Multiple sclerosis (MS) and POTS 
share some similar features. Typical 
age group is between 20 and 50 years, 
and women are more often affected in 
both conditions. Common symptoms 
include orthostatic intolerance, fatigue 
and anxiety. (Adamec et al. 2013a) In 
one prospective study (Adamec et al. 
2013b)  out of 112 patients diagnosed 
with relapsing remitting MS 21(18.8%) 
of them met the criteria for POTS. 
Seventeen of those patients were in 
relapse. Another study (Adamec et al. 
2013a) conducted on large sample of 
patients, divided into group of 112 MS 
patients and group of 181 patients with 
symptoms of OI, showed that POTS is 
more frequent in MS patients in 
comparison with patients with 
symptoms of OI with no neurological 
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illnesses. Connection between MS and 
POTS is explained by the presence of 
demyelinating brainstem and 
hemispheral lesions  which disrupt the 
physiological heart rate variability 
modulation. (Kanjwal et al. 2010) 
 
Inappropriate sinus tachycardia  
 
Inappropriate sinus tachycardia (IST) is 
a  form of arrhythmia which is 
characterized by an exaggerated 
increase in heart rate that is 
disproportionate to normal physiologic 
demands. IST shares some similarities 
with POTS. Patients with IST are also 
more often women, presenting 
symptoms are palpitations, fatigue, 
exercise intolerance and dizziness 
(Carew et al. 2009), IST can be 
triggered by orthostasis and minimal 
exertion, (Morillo & Guzmán 2007) 
exaggerated response to isoproterenol 
infusion can also be seen in IST. 
(Grubb 2008) Although sometimes it 
can be challenging to differentiate 
between POTS and IST, there are 
some distinguishing features that can 
help in making the correct diagnosis. 
POTS patients tend to display a more 
pronounced degree of postural change 
in HR than those with IST, and supine 
HR in POTS patients rarely exceeds 
100 bpm, which is common finding in 
patients with IST. (Carew et al. 2009; 
Grubb 2008) 
Other  
 
Migraine is found in about 42% of 
POTS patients. (Thieben et al. 2007) 
Joint hypermobility, irritable bowel 
syndrome, inﬂammatory bowel 
disease, mitral valve prolapse, and 
hypertension are frequently mentioned 
as co-morbidities associated with 
POTS. (Carew et al. 2009; Kanjwal et 
al. 2011; Thanavaro & Thanavaro 
2011; Raj 2006) POTS patients are 
sometimes diagnosed with anxiety 
disorders, but that might be due to a 
misinterpretation of their physical 
symptoms. Patients with POTS often 
have diminished attention and 
concentration. (Raj 2006) 
 
DIAGNOSTIC EVALUATION 
 
First, comprehensive history should be 
obtained and detailed examination 
should be performed with focus on 
previously described signs and 
symptoms. As mentioned before, 
cardinal criterion in diagnosing POTS 
is HR increase of ≥30 bpm or increase 
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of heart rate to ≥120 bpm within 10 min 
of standing or head-up tilt associated 
with symptoms of orthostatic 
intolerance and absence of orthostatic 
hypotension. Two tests can be used to 
assess patient's reaction to postural 
change. Passive head-up tilt 
table(HUT) test (Figure 1) is the 
standard method, which consists of 
two phases. In the first phase patient is 
placed on tilt table for a period of 5-20 
min in which supine HR and blood 
pressure (BP) is monitored. In the 
second phase patient is tilted to 60°-
80° and HR and BP are measured 
periodically or continuously for 10-
60min. (Carew et al. 2009; Abed et al. 
2012; Thanavaro & Thanavaro 2011; 
Kanjwal et al. 2010; Plash et al. 2013) 
Test should be performed in a quiet, 
dimly lit, temperature-controlled 
environment. (Carew et al. 2009) 
Period of time spent in supine or tilted 
position depends on protocol used. 
Another test is active stand test, which 
is considered to mimic real life. Patient 
is asked to assume upright position 
following a period of time spent in 
supine position. Whilst patient is 
standing unassisted, HR and BP is 
measured periodically. (Carew et al. 
2009; Abed et al. 2012; Raj 2006; 
Plash et al. 2013) Plash et al. (Plash et 
al. 2013) compared HUT to standing 
test in diagnosing POTS. In this study 
10-min standing was the most accurate 
test, when using ≥30 bpm HR 
increment criterion. Results in this 
study suggest that 10-min tilt test is 
highly sensitive (93%), but has poor 
specificity (40%), when using the ≥30 
bpm HR increment criterion. Plash et 
al. suggest that by increasing the HR 
criterion to 37 bpm test becomes much 
more specific (73%) while maintaining 
good sensitivity (80%). POTS is not 
diagnosed based solely on 
hemodynamic criteria. Clinical 
diagnosis of POTS requires history of 
orthostatic symptoms lasting ≥6 
months, worsening of symptoms with 
standing and relief with recumbence, 
absence of other causes of orthostatic 
symptoms or tachycardia (e.g. active 
bleeding, acute dehydration, 
medications) in addition to 
hemodynamic criteria. To differentiate 
hyperadrenergic from neuropathic type 
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of POTS supine and standing serum 
NE levels should be obtained. A high 
standing NE (>600pg/mL) identifies 
patients with hyperadrenergic POTS, 
and predicts their response to β-
blockade. (Thieben et al. 2007; Grubb 
2008) 
 
MANAGEMENT 
 
It is important to educate the patient 
about the nature of her/his disorder. 
Aggravating factors, such as heat or 
dehydration, should be avoided. 
Consumption of alcohol should be 
discouraged. (Thanavaro & Thanavaro 
2011) Patients should be taught three 
simple measures beneficial in 
improving orthostatic intolerance. The 
first measure is physical 
countermaneuvers. Patients contract 
muscles below the waist for about 30 
seconds, which results in reduced 
venous capacity and increased 
peripheral resistance. The second 
measure, which is especially helpful in 
patients who are hypovolemic, is 
wearing an abdominal binder. This 
reduces splanchnic-mesenteric venous 
capacity.The third measure is water 
bolus therapy which consist of drinking 
two 8-ounce (≈2 dL) glasses of water 
consecutively inducing  
sympathetically-mediated pressor 
response. (Low et al. 2009; Shannon 
et al. 2002) 
 
Nonpharmacotherapy 
 
Every POTS patient should be 
encouraged to begin a gradual 
program of physical reconditioning, 
with a goal of performing 20 to 30 min 
of aerobic activity 3 times a week. 
(Carew et al. 2009; Grubb 2008) In one 
study (Fu et al. 2010) 10 out of 19 
POTS patients that completed 3-month 
exercise training program no longer 
met the criteria for POTS. This and one 
other study (Winker et al. 2005) 
recorded increase in blood and plasma 
volume in patients who finished 3-
month training program. Winker et al. 
(Winker et al. 2005) demonstrated that 
training can result in shift from 
sympathetic to vagal predominance 
which might be beneficial for patients 
with OI. Many patients with POTS are 
hypovolemic. These patients should 
increase salt intake up to 10-20 g per 
day and obtain 2-2.5 L of fluids per 
day. (Carew et al. 2009; Raj 2006; Low 
et al. 2009) Acute blood volume 
expansion by applying 1 liter of 
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physiological saline intravenously is 
highly effective in controlling the HR 
and acutely improving POTS 
symptoms, but the treatment is not 
practical on a day to day basis. (Carew 
et al. 2009; Raj 2006) 
Pharmacological 
 
When nonpharmacological measures 
alone do not prove efficient, drugs are 
needed. (Mathias et al. 2012) The 
main goal of medications should be 
stabilization of the condition enough to 
enable POTS patients to undergo 
exercise training program. (Grubb 
2008) Patients with neuropathic type of 
POTS are best treated with 
combination of fludrocortisone and α-
agonist midodrine. (Low et al. 2009) 
Daily dose of fludrocortisone should 
not exceed 300μg to avoid adverse 
effects. Initial dose of midodrine should 
be 2.5 mg, three times a day before 
meals and can be increase if needed  
to maximum recommended daily dose 
of 30 mg. (Mathias et al. 2012) Some 
patients have better response when 
midodrine is combined with 
acetylcholinesterase inhibitor 
pyridostigmine, at the dose of 60 mg 3 
t.i.d. (Low et al. 2009) Pyridostigmine 
appears to be most effective in patients 
with postviral onset of POTS. (Grubb 
2008) In patients who are 
unresponsive to above-mentioned 
therapy, selective serotonin reuptake 
inhibitor (SSRI) or norepinephrine 
reuptake inhibitor can be added. 
Octreotide administered by 
subcutaneous injection beginning at 50 
μg 2-3 times daily is an additional 
therapy for refractory patients. (Grubb 
2008) Octreotide can be beneficial in 
patients with marked postprandial 
symptoms. (Mathias et al. 2012)  
Patients with hyperadrenergic form of 
POTS often respond best to agents 
that block norepinephrine or its effects. 
(Grubb 2008) Dual-acting  β-blocker, 
such as carvedilol or labetalol, may be 
more effective than a pure β-blocker 
(e.g. propranolol). Recommended 
dosage for carvedilol and labetalol is 
3.125-6.25 mp p.o. twice daily and 
100-200 mg p.o. two times a day 
respectively. (Thanavaro & Thanavaro 
2011) Central sympatholytic 
medications, such as clonidine, is often 
used in patients with hyperadrenergic 
POTS. Clonidine, alpha 2 agonist, is 
administered orally or in the patch form 
0.1-0.3 mg twice daily. (Mathias et al. 
2012; Grubb 2008; Raj 2006) 
Ivabradine, sinus  node  blocker, is 
beneficial in some POTS patients. 
According to one retrospective case 
series (McDonald et al. 2011) 
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ivabradine appears to control 
symptoms associated with POTS with 
effectiveness similar to that of 
conventional treatment.  
According to Thieben et al. (Thieben et 
al. 2007) most commonly prerscribed 
medication are β-blockers (76.7%), 
followed by SSRI (51.7%), 
fludrocortisone (39.5%) and midodrine 
(31.6%).  
 
PROGNOSIS 
 
Younger patients and those with 
postviral onset of POTS have better 
prognosis. Over one half of those with 
postviral onset make reasonable 
recovery over 2-5 years and are able 
to performe activities of everyday life 
with minimal restriction. Approximately 
90% of patients will respond to 
combination of physical and 
pharmacological therapy, but patients 
with hyperadrenergic POTS will likely 
require therapy indefinitely. Majority of 
patients experience substantial 
improvement, after correct diagnosis 
and suitable therapy. (Grubb 2008; 
Sandroni et al. 1999; Sousa et al. 
2012) 
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